Skip to main content

Table 1 Baseline characteristics of 380 efavirenz and 281 atazanavir initiators.

From: Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

Patient Characteristics*

Efavirenz initiators

(N = 380)

Atazanavir initiators

(N = 281)

P-value**

Study site

  

<0.0001

Navy

32%

25%

 

MACS

33%

15%

 

WIHS

36%

60%

 

Male

63%

38%

<0.0001

Race/Ethnicity

  

<0.0001

Caucasian (Hispanic & Non Hispanic)

43%

28%

 

African-American (Hispanic & Non-Hispanic)

46%

49%

 

Hispanic (non-white, non-black) & other

11%

22%

 

Age at switch/initiation

41 (34, 47)

41 (35, 46)

0.91

Medical History

   

Diabetes Mellitus

11%

17%

0.03

Thyroid Disease

3%

6%

0.07

Hepatitis C antibody status

15%

19%

0.18

Treatment Characteristics

   

HAART initiation date

Aug 2001

(Aug 97-Sep03)

Dec 1998

(May 97-Sep 02)

0.003

ART-naïve at initiation

34%

12%

<0.0001

Class-naïve at initiation

80%

30%

<0.0001

Years of HAART exposure at initiation

0.5 (0.1, 2.9)

3.6 (1.2, 5.7)

<0.0001

Atazanavir regimen included Ritonavir

 

79%

 

HIV biomarkers prior to initiation

   

CD4+ cell count

332 (216, 464)

289 (202, 462)

0.11

Log10 HIV RNA

4.15 (2.65, 4.75)

4.01 (2.59,4.76)

0.42

Viral load <80 copies/mL

19%

17%

0.50

Post-initiation HIV characteristics***

   

CD4+ cell count

434 (303, 581)

410 (241, 575)

0.02

Log10 HIV RNA

1.90 (1.90, 2.38)

1.90 (1.90, 2.51)

<0.0001

Viral load <80 copies/mL

68%

58%

0.0003

NRTI backbone included

   

TDF or ABC & D4T, DDI, or AZT

19%

28%

0.0003

   TDF or ABC but not D4T, DDI, or AZT

32%

58%

<0.0001

   D4T, DDI, or AZT but not TDF or ABC

49%

14%

<0.0001

  1. * Median (IQR) for continuous characteristics ** From chi-square tests (categorical) or Wilcoxon rank sum test (continuous) *** Collapsed across all follow-up